Skip to main content

Table 1 Selected characteristics of the study population: 191 cases, 417 controls.

From: HOXB13:IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive disease

  Cases Controls
Characteristic n(%) n(%)
Matched variables
   Age at diagnosis (years)
<40 15(8%) 20(5%)
40-49 33(17%) 94(22%)
50-59 59(31%) 113(27%)
60-74 84(44%) 190(46%)
   Race/ethnicity
White, non-Hispanic 146(76%) 326(78%)
White, Hispanic 7(4%) 11(3%)
Black 19(10%) 42(10%)
Asian 19(10%) 38(9%)
   Surgery year
1985-1989 127(66%) 278(67%)
1990-1994 64(34%) 139(33%)
   Adjuvant tamoxifen
No 134(70%) 281(67%)
Yes 57(30%) 136(33%)
Unmatched variables
   Tumor size (cm)
≤ 1.0 40(21%) 128(31%)
1.1-2.0 84(44%) 187(45%)
2.1-4.0 63(33%) 96(23%)
>4.0 4(2%) 6(1%)
   Tumor grade (differentiation)1
Well 21(11%) 123(29%)
Moderate 79(41%) 182(44%)
Poor 91(48%) 112(27%)
   ER status from RT-PCR2
Positive 145(76%) 370(89%)
Negative 46(24%) 47(11%)
   PR status from RT-PCR2
Positive 117(61%) 324(78%)
Negative 74(39%) 93(22%)
   HER2 status from RT-PCR2
Positive 33(17%) 41(10%)
Negative 158(83%) 376(90%)
   HOXB13:IL17BR   
Low risk 71(37%) 222(53%)
High risk 120(63%) 195(47%)
   MGI   
Low risk 51(27%) 197(47%)
High risk 140(73%) 220(53%)
   MGI+HOXB13:IL17BR   
Low risk 51(27%) 197(47%)
Intermediate risk 50(26%) 108(26%)
High risk 90(47%) 112(27%)
   BCI   
Low risk 55(29%) 222(53%)
Intermediate risk 54(28%) 85(20%)
High risk 82(43%) 110(26%)
  1. 1Modified Bloom-Richardson grading criteria; 2performed by Genomic Health, Inc. (ER cut points ≤ 6.5 and >6.5 units; PR cut points <5.5 and ≥5.5 units; HER2 cut points <11.5 and ≥11.5 units).